Treatment of cystoid macular edema after cataract surgery. 2017

Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
From the University Eye Clinic Maastricht (Wielders, Schouten, Aberle, Lambermont, van den Biggelaar, Simons, Nuijts), Maastricht University Medical Center, and the Department of Methodology and Statistics, Maastricht University (Winkens), Maastricht, the Netherlands. Electronic address: laura.wielders@mumc.nl.

The purpose of this review was to determine the optimum pharmacologic treatment for cystoid macular edema (CME) after cataract surgery in nondiabetic and diabetic patients. The Cochrane Library, Medline, and Embase databases were searched, and all randomized controlled trials (RCTs) that compared at least 2 pharmacologic strategies for CME after cataract surgery were included. Studies were excluded if preoperative CME or other risk factors for developing CME postoperatively were present. Ten RCTs were included in the systematic review. Five trials included at least 30 participants. Three RCTs showed a greater visual acuity improvement in patients treated with topical nonsteroidal antiinflammatory drugs (NSAIDs) than with a placebo. Other studies comparing the efficacy of topical NSAIDs, topical corticosteroids, sub-Tenon corticosteroids, oral NSAIDs, and oral acetazolamide did not report significant differences between treatment groups. Therefore, large RCTs are needed to provide evidence-based recommendations for the optimum treatment of CME after cataract surgery.

UI MeSH Term Description Entries
D008269 Macular Edema Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90) Central Retinal Edema, Cystoid,Cystoid Macular Edema,Macular Edema, Cystoid,Cystoid Macular Dystrophy,Cystoid Macular Edema, Postoperative,Irvine-Gass Syndrome,Macular Dystrophy, Dominant Cystoid,Edema, Cystoid Macular,Edema, Macular,Irvine Gass Syndrome,Syndrome, Irvine-Gass
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D002387 Cataract Extraction The removal of a cataractous CRYSTALLINE LENS from the eye. Enzymatic Zonulolysis,Phakectomy,Cataract Extractions,Enzymatic Zonulolyses,Extraction, Cataract,Extractions, Cataract,Phakectomies,Zonulolyses, Enzymatic,Zonulolysis, Enzymatic
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014792 Visual Acuity Clarity or sharpness of OCULAR VISION or the ability of the eye to see fine details. Visual acuity depends on the functions of RETINA, neuronal transmission, and the interpretative ability of the brain. Normal visual acuity is expressed as 20/20 indicating that one can see at 20 feet what should normally be seen at that distance. Visual acuity can also be influenced by brightness, color, and contrast. Acuities, Visual,Acuity, Visual,Visual Acuities

Related Publications

Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
December 2018, Journal of cataract and refractive surgery,
Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
December 1976, American journal of ophthalmology,
Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
February 2003, Current opinion in ophthalmology,
Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
April 2018, Journal of cataract and refractive surgery,
Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
January 1995, Journal francais d'ophtalmologie,
Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
February 2000, Current opinion in ophthalmology,
Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
February 1989, Archives of ophthalmology (Chicago, Ill. : 1960),
Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
July 1988, Archives of ophthalmology (Chicago, Ill. : 1960),
Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
September 1999, Ophthalmology,
Laura H P Wielders, and Jan S A G Schouten, and Merel R Aberle, and Verena A Lambermont, and Frank J H M van den Biggelaar, and Bjorn Winkens, and Rob W P Simons, and Rudy M M A Nuijts
March 2016, Ophthalmology,
Copied contents to your clipboard!